Miragen Therapeutics Inc (MGEN)
B.Riley FBR analyst Madhu Kumar reiterated a Buy rating on Miragen Therapeutics Inc yesterday and set a price target of $18.50. The company’s shares opened today at $6.98.
“This morning, miRagen Therapeutics (MGEN) announced the start of a Phase II trial of miR-29b mimic MRG-201 in keloids. While a positive event for the company, we reiterate that the key near-term value driver for MGEN shares in the start of the Phase II SOLAR trial of lead asset, miR-155 inhibitor cobomarsen, in mycosis fungoides (MF), guided to start in 2H18. We thus reiterate our MGEN Buy rating and $18.50 PT.”
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 36.6% and a 57.9% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Deciphera Pharmaceuticals Inc, and Clementia Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Miragen Therapeutics Inc with a $18.83 average price target, a 169.8% upside from current levels. In a report released yesterday, Oppenheimer also initiated coverage with a Buy rating on the stock with a $19 price target.
B.Riley FBR analyst David Buck reiterated a Buy rating on Shire yesterday and set a price target of $200. The company’s shares opened today at $172.11, close to its 52-week high of $177.51.
“We reiterate our Buy rating for Shire ADS with our 12-month price target of $200 per share. The FTC has cleared the combination of Shire plc and Takeda without conditions, which was expected given the lack of meaningful overlap and Shire’s prior decision to divest its oncology business. We continue to see a 1H19 approval as reasonable subject to shareholder votes and additional antitrust clearances. Shire ADS trade at a significant discount to the current value of the Takeda offer even though Takeda shares have dropped by ~28% year-to-date on the Tokyo exchange. Takeda’s offer in Shire ADS (representing three ordinary shares) represents the following: cash per share of $90.99 plus 2.517 new Takeda shares or 5.034 Takeda ADS.”
According to TipRanks.com, Buck is a 4-star analyst with an average return of 17.3% and a 73.6% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.
Currently, the analyst consensus on Shire is a Strong Buy with an average price target of $201.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.